Table 3 MIP-based specific recognition intended for cancer therapy
From: Molecularly imprinted polymers (MIPs): emerging biomaterials for cancer theragnostic applications
Type of therapy | MIPa components | Template | MITa strategy | Therapeutic agents | Targeted cancer | Reference |
|---|---|---|---|---|---|---|
Drug delivery | Monomer: VPBA, AMMH Crosslinker: BAC, EGDMA | SA | Precipitation polymerization (Surface imprinting) | Nitric oxide (NO) | Hepatocellular carcinoma (HepG2 cells) | [129] |
Monomer: NIPAm, TBA, APMA Crosslinker: MBA | C-terminal linear peptide of EFGR | Solid phase method (Surface imprinting) | DOX | Breast cancer (MDA-MA-468 cells) | [126] | |
Monomer: TFMA, DMAEMA, NIPA, TBAm Crosslinker: BAC | N-terminal epitope of CD59 glycoprotein | Free radical polymerization (Surface imprinting) | DOX | Breast cancer (MCF-7 cells) | [131] | |
Monomer: Zinc acrylate, acrylamide Crosslinker: EDGMA | HER2, DOX | Free radical polymerization (Epitope imprinting) | DOX | Breast cancer (SK-BR-3 cells) | [27] | |
Monomer: Zinc acrylate, VPBA Crosslinker: EDGMA | 71–80 peptides of FN14, BLM | Free radical polymerization (Epitope imprinting) | Bleomycin | Pancreatic cancer (BxPC-3 cells) | [138] | |
Photothermal therapy | Monomer: DA, APBA Crosslinker: DA | SA | Self-polymerization (Surface imprinting) | PDA | Breast cancer (MCF-7 cells) Hepatocellular carcinoma (HepG2 cells) | [145] |
Photothermal therapy + Drug delivery | Monomer: DA Crosslinker: DA | Epitope of EGFR, DOX | Self-polymerization (Epitope imprinting) | PDA + DOX | Breast cancer (MDA-MB-468 cells) Lung cancer A549 cells | [153] |
Photothermal therapy + Immunotherapy | Monomer: DA Crosslinker: DA | HSA | Self-polymerization (Surface imprinting) | PDA + PD-L1 antibody | Breast cancer (4T1 cells) | [157] |
Photodynamic therapy | Monomer: PSMAB + CB | SA | Precipitation polymerization (Surface imprinting) | Photosensitizer (CB) | Prostate cancer (DU 145 cells) | [164] |
Monomer: EVAL Crosslinker: BAC | Peptide sequence from PD-L1 | Precipitation polymerization (Epitope imprinting) | Photosensitizer (MC540) | Liver cancer (HepG2 cells) | [163] | |
Photodynamic therapy + Drug delivery | Monomer: NIPAm, TBAm, AAM Crosslinker: BIS | Epitope peptides of CD59, DOX | Free radical polymerization (Epitope imprinting) | Photosensitizer (Ce6) + DOX | Breast cancer (MCF-7 cells) | [162] |
Enzyme inhibitor | Monomer: NIPAAm Crosslinker: MBAAm | Trypsin | Solid phase method (Surface imprinting) | MIP_trypsin itself as therapeutic | Trypsin-induced cell injury | [173] |
Monomer: Mercapto-propyl-trimethoxy-silane, N‐(2‐aminoethyl)‐3‐aminopropyltrimethoxy silane | Active center of DHFR | Sol–gel method (Surface imprinting) | MIP-CTPB itself as therapeutic | DHFR-induced DNA synthesis | [175] | |
Immune checkpoint blockade therapy | Monomer: TEOS | N-glycans of PD-L1 glycoprotein | Surface imprinting | NanoNiche itself as therapeutic | HER2+ breast cancer | [176] |
Blocking signaling pathway | Monomer: TEOS | N-glycans of HER2 glycoprotein | Surface imprinting | NanoMIP itself as therapeutic | Breast cancer (MDA-MB-231 cells) | [185] |